NSRX Company Profile and Key Details

Nasus Pharma Ltd. (AMEX:NSRX) closed at $3.08 USD, gaining $0.01 (0.33%) from the previous close of $3.07. The stock is currently mid-range between its 52-week high and low $1.98 and $9.99. With a market capitalization of about $26.53 million, Nasus Pharma Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~4.29). Key stats such as the average daily volume over the past year has been around 82.17 thousand shares, volume is running light vs its 52-week average. Headquartered in Tel Aviv, None, Nasus Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Dan Teleman, the company employs approximately 2 people and listed since August 13, 2025. Nasus Pharma Ltd. is a specialized pharmaceutical firm currently advancing through clinical trials.

NSRX has shown weak momentum, losing -10.68% over the past week and -4.26% over the past quarter, though year-to-date performance is down -28.74%. Short-term trend indicators are bullishly aligned (SMA20 -7.9%, SMA50 -21.08%, SMA200 -29.02%). The stock’s 14-day RSI is 41.5 (neutral), while the ATR of 0.69 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.95% below its high and over 4.08% above its low. Average 10-day trading volume of 38.45 thousand shares is below the 3-month average of 89.12 thousand, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Nasus Pharma Ltd. trades at a P/E ratio of -18.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 The P/FCF stands at 0.0, also above market averages.

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $18.00. The high target offers 616.61% upside. The low target suggests 486.32% downside. The mean target is $19.67. This offers 540.72% upside.

Nasus Pharma Ltd. has 9.06 million shares outstanding. The public float is 2.49 million shares, elevated short interest at 0.31% of float. This equals 12.25 thousand shares. The short ratio is 0.09 days. Institutional investors hold 0.0% of the float. Insiders own 59.33%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Our AI price prediction model suggests that Nasus Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 131.6%, reaching $7.11 by September 14, 2026, with a range of $6.96 to $7.25. 1-Year Outlook: Projected loss of -85.02%, with price at $0.46 by June 16, 2027, within a range of $0.35 to $0.55.

Nasus Pharma Ltd. (AMEX:NSRX) shares are down -28.74% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Nasus Pharma Ltd. trading at a premium to the broader market with a P/E of -18.33. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $19.67, suggesting 540.72% upside.